Abstract
Male breast cancer is a rare disease, accounting for only 1 % of breast cancer diagnoses in the USA. The current literature suggests that genetic factors including BRCA2 mutations, family history, age, androgen/estrogen imbalance, and environmental exposures may predispose to male breast cancer. In this manuscript, we will review known and possible risk factors for male breast cancer, as well as describe the clinical patterns of the disease.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Siegel R et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.
Jepson AS, Fentiman IS. Male breast cancer. Int J Clin Pract. 1998;52(8):571–6.
Giordano SH et al. Breast carcinoma in men: a population-based study. Cancer. 2004;101(1):51–7.
Society, A.C. Cancer facts and figures 2015. Atlanta: American Cancer Society; 2015.
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (editors). SEER cancer statistics review, 1975–2011. Bethesda, Maryland: National Cancer Institute.
Cardoso F, Bartlett J, Giordano S, et al., Characterization of male breast cancer: first results of the EORTC10085/TBCRC/BIG/NABCG International Male BC Program, in 2014 San Antonio Breast Cancer Symposium 2014, European Organization for Research and Treatmento of Cancer: San Antonio, Texas. This study is the largest collection of male breast cancer biologic samples and clinical characteristics to date. All clinical data and pathology were centrally reviewed for 1473 eligible patients who were treated from 1990 to 2010. The authors report on clinical characteristic and overall survival in male breast cancer patients.
Goss PE et al. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years: 1955–1996. Cancer. 1999;85(3):629–39.
Masci G et al. Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series. Oncologist. 2015;20(6):586–92. In this study, Masci et al. evaluated the cliniopathologic characteristics of 97 male breast cancer specimens and found substantial differences than what it typically seen in female breast cancer. Male breast cancer showed higher rates of hormone receptor positivity and lower rates of HER2 overexpression. Furthermore, higher proliferative index and higher grade were associated with shorter overall survival.
Gnerlich JL et al. Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration. Ann Surg Oncol. 2011;18(7):1837–44.
Chung HC et al. Expression of prognostic factors (EGFR, ER) by immunohistochemical staining method in male breast cancer. Yonsei Med J. 1991;32(2):126–30.
Fox SB et al. Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. J Pathol. 1992;166(1):13–8.
Dawson PJ, Paine TM, Wolman SR. Immunocytochemical characterization of male breast cancer. Mod Pathol Off J U S Can Acad Pathol Inc. 1992;5(6):621–5.
Anderson WF et al. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(2):232–9.
Arslan UY et al. Outcome of non-metastatic male breast cancer: 118 patients. Med Oncol. 2012;29(2):554–60.
Moore J et al. Prognostic indicators in male breast carcinoma. Breast J. 1998;4(4):261–9.
Leach IH, Ellis IO, Elston CW. c-erb-B-2 expression in male breast carcinoma. J Clin Pathol. 1992;45(10):942.
Willsher PC et al. Male breast cancer: pathological and immunohistochemical features. Anticancer Res. 1997;17(3C):2335–8.
Leone JP et al. Prognostic significance of tumor subtypes in male breast cancer: a population-based study. Breast Cancer Res Treat. 2015;152(3):601–9.
Anderson WF et al. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat. 2004;83(1):77–86.
Shak S, Palmer G, Baehner FL, Millward C, Watson D, Sledge Jr GW. Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: first large genomic study of 347 male breast cancers compared to 82,434 female breast cancers. J Clin Oncol (Meet Abstr). 2009;27:549.
Jamy O et al. Male breast cancer: a 24 year experience of a tertiary care hospital in Pakistan. Asian Pac J Cancer Prev APJCP. 2015;16(4):1559–63.
Albasri A et al. Histopathological features of breast cancer in Al-Madinah region of Saudi Arabia. Saudi Med J. 2014;35(12):1489–93.
Salehi A et al. Survival of male breast cancer in Fars, South of Iran. Iran Red Crescent Med J. 2011;13(2):99–105.
Tawil AN et al. Clinicopathologic and immunohistochemical characteristics of male breast cancer: a single center experience. Breast J. 2012;18(1):65–8.
Ndom P et al. A meta-analysis of male breast cancer in Africa. Breast. 2012;21(3):237–41.
Miao H et al. Incidence and outcome of male breast cancer: an international population-based study. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(33):4381–6.
Chavez-Macgregor M et al. Male breast cancer according to tumor subtype and race: a population-based study. Cancer. 2013;119(9):1611–7.
Sineshaw HM et al. Black/White disparities in receipt of treatment and survival among men with early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(21):2337–44.
O’Malley CD et al. Racial/ethnic differences in survival rates in a population-based series of men with breast carcinoma. Cancer. 2002;94(11):2836–43.
Johnson KC, Pan S, Mao Y. Risk factors for male breast cancer in Canada, 1994–1998. Eur J Cancer Prev Off J Eur Cancer Prev Organ. 2002;11(3):253–63.
Ewertz M et al. Risk factors for male breast cancer—a case–control study from Scandinavia. Acta Oncol. 2001;40(4):467–71.
Lenfant-Pejovic MH et al. Risk factors for male breast cancer: a Franco-Swiss case–control study. Int J Cancer. 1990;45(4):661–5.
Brinton LA et al. Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst. 2008;100(20):1477–81.
D’Avanzo B, La Vecchia C. Risk factors for male breast cancer. Br J Cancer. 1995;71(6):1359–62.
Rosenblatt KA et al. Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst. 1991;83(12):849–54.
Casagrande JT et al. A case–control study of male breast cancer. Cancer Res. 1988;48(5):1326–30.
Basham VM et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res BCR. 2002;4(1):R2.
Ottini L et al. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res. 2003;63(2):342–7.
Boyd J et al. Male breast cancer in the hereditary nonpolyposis colorectal cancer syndrome. Breast Cancer Res Treat. 1999;53(1):87–91.
Fackenthal JD et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet. 2001;38(3):159–64.
Ruddy KJ, Winer EP. Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(6):1434–43.
Holloman WK. Unraveling the mechanism of BRCA2 in homologous recombination. Nat Struct Mol Biol. 2011;18(7):748–54.
Couch FJ et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet. 1996;13(1):123–5.
Friedman LS et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet. 1997;60(2):313–9.
Easton DF et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet. 1997;61(1):120–8.
Thompson D, Easton D. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet. 2001;68(2):410–9.
Kwiatkowska E et al. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9(12):4452–9.
Thorlacius S et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 1997;60(5):1079–84.
Struewing JP et al. Founder BRCA1/2 mutations among male patients with breast cancer in Israel. Am J Hum Genet. 1999;65(6):1800–2.
Sverdlov RS et al. Genetic analyses of male breast cancer in Israel. Genet Test. 2000;4(3):313–7.
Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature. 2000;408(6811):433–9.
Meijers-Heijboer H et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31(1):55–9.
Neuhausen S et al. Role of CHEK2*1100delC in unselected series of non-BRCA1/2 male breast cancers. Int J Cancer. 2004;108(3):477–8.
Falchetti M et al. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. Breast Cancer Res Treat. 2008;110(1):161–7.
Martinez-Bouzas C et al. CHEK2 1100delC is present in familial breast cancer cases of the Basque Country. Breast Cancer Res Treat. 2007;103(1):111–3.
Caligo MA et al. The CHEK2 c.1100delC mutation plays an irrelevant role in breast cancer predisposition in Italy. Hum Mutat. 2004;24(1):100–1.
Weischer M et al. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(1):57–63.
Rizzolo P et al. Male breast cancer: genetics, epigenetics, and ethical aspects. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24(8):viii75–82.
Young IE et al. A polymorphism in the CYP17 gene is associated with male breast cancer. Br J Cancer. 1999;81(1):141–3.
Harnden DG, Maclean N, Langlands AO. Carcinoma of the breast and Klinefelter’s syndrome. J Med Genet. 1971;8(4):460–1.
Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist. 2005;10(7):471–9.
Hultborn R et al. Prevalence of Klinefelter’s syndrome in male breast cancer patients. Anticancer Res. 1997;17(6D):4293–7.
Newman J. Breast cancer in men and mammography of the male breast. Radiol Technol. 1997;69(1):17–28. quiz 29–36.
Scheike O, Visfeldt J, Petersen B. Male breast cancer. 3. Breast carcinoma in association with the Klinefelter syndrome. Acta Pathol Microbiol Scand A Pathol. 1973;81(3):352–8.
Lynch HT, Watson P, Narod SA. The genetic epidemiology of male breast carcinoma. Cancer. 1999;86(5):744–6.
Evans DB, Crichlow RW. Carcinoma of the male breast and Klinefelter’s syndrome: is there an association? CA Cancer J Clin. 1987;37(4):246–51.
Thomas DB et al. Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol. 1992;135(7):734–48.
Mester J, Eng C. Cowden syndrome: recognizing and managing a not-so-rare hereditary cancer syndrome. J Surg Oncol. 2015;111(1):125–30.
Ottini L et al. Male breast cancer. Crit Rev Oncol Hematol. 2010;73(2):141–55.
Brinton LA et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. J Natl Cancer Inst. 2014;106(3):djt465.
Hsing AW et al. Risk factors for male breast cancer (United States). Cancer Causes Control CCC. 1998;9(3):269–75.
Brinton LA et al. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(18):2041–50.
Longcope C et al. Estrogen and androgen dynamics in liver disease. J Endocrinol Investig. 1984;7(6):629–34.
Guechot J et al. Sex hormone imbalance in male alcoholic cirrhotic patients with and without hepatocellular carcinoma. Cancer. 1988;62(4):760–2.
Sorensen HT et al. Risk of breast cancer in men with liver cirrhosis. Am J Gastroenterol. 1998;93(2):231–3.
Mills PR et al. Primary biliary cirrhosis: an increased incidence of extrahepatic malignancies? J Clin Pathol. 1982;35(5):541–3.
Goudie BM et al. Breast cancer in women with primary biliary cirrhosis. Br Med J. 1985;291(6509):1597–8.
Wolke AM et al. Malignancy in primary biliary cirrhosis. High incidence of breast cancer in affected women. Am J Med. 1984;76(6):1075–8.
Floreani A et al. Hepatic and extrahepatic malignancies in primary biliary cirrhosis. Hepatology. 1999;29(5):1425–8.
Rubino A, Fissi S, Secreto G. Bilateral breast cancer in a male patient with hepatocellular carcinoma. A case report. Ann Ital Chir. 2008;79(2):117–9.
Yoneda S et al. Breast cancer developed in a male patient with liver cirrhosis bearing hepatocellular carcinoma. Am J Gastroenterol. 2000;95(2):556–7.
Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published case–control studies and discussion of selected aetiological factors. Int J Cancer. 1993;53(4):538–49.
Thomas E. Original research: men’s awareness and knowledge of male breast cancer. Am J Nurs. 2010;110(10):32–7. 39–40; quiz 41–2.
Thomas DB et al. Ionizing radiation and breast cancer in men (United States). Cancer Causes Control CCC. 1994;5(1):9–14.
Mabuchi K, Bross DS, Kessler II. Risk factors for male breast cancer. J Natl Cancer Inst. 1985;74(2):371–5.
Pollan M, Gustavsson P, Floderus B. Breast cancer, occupation, and exposure to electromagnetic fields among Swedish men. Am J Ind Med. 2001;39(3):276–85.
Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137(8):678–87.
Bove FJ et al. Mortality study of civilian employees exposed to contaminated drinking water at USMC Base Camp Lejeune: a retrospective cohort study. Environ Health Glob Access Sci Sour. 2014;13:68.
Cocco P et al. Case–control study of occupational exposures and male breast cancer. Occup Environ Med. 1998;55(9):599–604.
Feychting M et al. Magnetic fields and breast cancer in Swedish adults residing near high-voltage power lines. Epidemiology. 1998;9(4):392–7.
Stenlund C, Floderus B. Occupational exposure to magnetic fields in relation to male breast cancer and testicular cancer: a Swedish case–control study. Cancer Causes Control CCC. 1997;8(2):184–91.
Matanoski GM, Breysse PN, Elliott EA. Electromagnetic field exposure and male breast cancer. Lancet. 1991;337(8743):737.
Theriault G et al. Cancer risks associated with occupational exposure to magnetic fields among electric utility workers in Ontario and Quebec, Canada, and France: 1970–1989. Am J Epidemiol. 1994;139(6):550–72.
Guenel P et al. Incidence of cancer in persons with occupational exposure to electromagnetic fields in Denmark. Br J Ind Med. 1993;50(8):758–64.
Stalsberg H et al. Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Control CCC. 1993;4(2):143–51.
Wick MR et al. Low-stage carcinoma of the male breast. A histologic, immunohistochemical, and flow cytometric comparison with localized female breast carcinoma. Am J Clin Pathol. 1999;111(1):59–69.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Raina M. Ferzoco and Kathryn J. Ruddy declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Funding
This publication was made possible by CTSA grant numbers UL1 TR000135 and KL2TR000136-09 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.
Additional information
This article is part of the Topical Collection on Breast Cancer
Rights and permissions
About this article
Cite this article
Ferzoco, R.M., Ruddy, K.J. The Epidemiology of Male Breast Cancer. Curr Oncol Rep 18, 1 (2016). https://doi.org/10.1007/s11912-015-0487-4
Published:
DOI: https://doi.org/10.1007/s11912-015-0487-4